Abstract
Seven hundred twenty-three isolates of Moraxella catarrhalis obtained from outpatients with a variety of infections in 30 medical centers in the United States between 1 November 1994 and 30 April 1995 were characterized in a central laboratory. The overall rate of beta-lactamase production was 95.3%. When the National Committee for Clinical Laboratory Standards MIC interpretive breakpoints for Haemophilus influenzae were applied, percentages of strains found to be susceptible to selected oral antimicrobial agents were as follows: azithromycin, clarithromycin, and erythromycin, 100%; tetracycline and chloramphenicol, 100%; amoxicillin-clavulanate, 100%; cefixime, 99.3%; cefpodoxime, 99.0%; cefaclor, 99.4%; loracarbef, 99.0%; cefuroxime, 98.5%; cefprozil, 94.3%; and trimethoprim-sulfamethoxazole, 93.5%.
Full Text
The Full Text of this article is available as a PDF (170.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barry A. L., Pfaller M. A., Fuchs P. C., Packer R. R. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob Agents Chemother. 1994 Oct;38(10):2419–2425. doi: 10.1128/aac.38.10.2419. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brown B. A., Wallace R. J., Jr, Flanagan C. W., Wilson R. W., Luman J. I., Redditt S. D. Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis. Antimicrob Agents Chemother. 1989 Sep;33(9):1631–1633. doi: 10.1128/aac.33.9.1631. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Doern G. V. Branhamella catarrhalis--an emerging human pathogen. Diagn Microbiol Infect Dis. 1986 Mar;4(3):191–201. doi: 10.1016/0732-8893(86)90098-2. [DOI] [PubMed] [Google Scholar]
- Doern G. V., Tubert T. A. In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods. Antimicrob Agents Chemother. 1988 Feb;32(2):259–261. doi: 10.1128/aac.32.2.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Farmer T., Reading C. beta-Lactamases of Branhamella catarrhalis and their inhibition by clavulanic acid. Antimicrob Agents Chemother. 1982 Mar;21(3):506–508. doi: 10.1128/aac.21.3.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jorgensen J. H., Doern G. V., Maher L. A., Howell A. W., Redding J. S. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 1990 Nov;34(11):2075–2080. doi: 10.1128/aac.34.11.2075. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kirby P., Dunne A., King D. H., Corey L. Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. Am J Med. 1990 May;88(5):465–469. doi: 10.1016/0002-9343(90)90424-c. [DOI] [PubMed] [Google Scholar]
- Marchant C. D. Spectrum of disease due to Branhamella catarrhalis in children with particular reference to acute otitis media. Am J Med. 1990 May 14;88(5A):15S–19S. doi: 10.1016/0002-9343(90)90255-c. [DOI] [PubMed] [Google Scholar]
- Nash D. R., Wallace R. J., Jr, Steingrube V. A., Shurin P. A. Isoelectric focusing of beta-lactamases from sputum and middle ear isolates of Branhamella catarrhalis recovered in the United States. Drugs. 1986;31 (Suppl 3):48–54. doi: 10.2165/00003495-198600313-00012. [DOI] [PubMed] [Google Scholar]
- Stobberingh E. E., van Eck H. J., Houben A. W., van Boven C. P. Analysis of the relationship between ampicillin resistance and beta-lactamase production in Branhamella catarrhalis. Drugs. 1986;31 (Suppl 3):23–27. doi: 10.2165/00003495-198600313-00007. [DOI] [PubMed] [Google Scholar]